Research programme: indene derivatives - ADT Pharmaceuticals
Alternative Names: ADT-006; MCI 020; MCI-030; Pan-RAS programme; PDE10/β-catenin programmeLatest Information Update: 28 Apr 2024
Price :
$50 *
At a glance
- Originator ADT Pharmaceuticals
- Developer ADT Pharmaceuticals; Chemomab Therapeutics
- Class Antineoplastics; Indenes; Small molecules
- Mechanism of Action Phosphodiesterase 10A inhibitors; Ras protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer; Colorectal cancer; Malignant melanoma
Most Recent Events
- 28 Apr 2024 No recent reports of development identified for preclinical development in Cancer in USA
- 28 Apr 2023 No recent reports of development identified for preclinical development in Colorectal-cancer in USA (PO)
- 13 Jun 2021 Chemomab therapeutics has patent protection for pan RAS, PDE10 catenin program in USA, Japan, China, Australia, Europe, Hong Kong before June 2021